Xeljanz(潰瘍性大腸炎)：市場分析と予測（～2022）...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 6
1.2 List of Figures 7
2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 8
2.3 Upcoming Related Reports 10
3 Disease Overview 11
3.1 Etiology and Pathophysiology 11
3.1.1 Etiology 11
3.1.2 Pathophysiology 13
3.2 Symptoms 15
3.2.1 Quality of Life 15
4 Disease Management 17
4.1 Diagnosis and Treatment Overview 17
4.1.1 Diagnosis 17
4.1.2 Treatment Guidelines and Leading Prescribed Drugs 20
4.1.3 Clinical Practice 22
5 Competitive Assessment 26
5.1 Overview 26
5.2 Strategic Competitor Assessment 27
6 Opportunity and Unmet Need 29
6.1 Overview 29
6.2 Unmet Needs 30
6.2.1 Curative Therapy for Severe UC Patients 30
6.2.2 Diagnostic Markers for Disease Severity 30
6.2.3 Personalized Therapy 31
6.2.4 A Replacement for Steroids 31
6.2.5 Novel Oral Drug Formulations 32
6.2.6 Preventative Medicine for Lowering the Associated Colorectal Cancer Risk 33
6.2.7 Improved Management of Infectious Adverse Events 33
6.3 Unmet Needs Gap Analysis 34
6.4 Disease Severity and Colorectal Cancer Biomarker-Based Prognostic Tools 35
6.5 Predictors of Medically-Refractory Disease 36
7 Pipeline Assessment 37
7.1 Overview 37
7.2 Promising Drugs in Clinical Development 37
8 Xeljanz (tofacitinib) 39
8.1 Overview 39
8.2 Efficacy 40
8.3 Safety 41
8.4 Dosing and Formulation 43
8.5 Potential Clinical Positioning 43
8.6 Potential Commercial Positioning 43
8.7 Pricing and Reimbursement 43
8.8 SWOT Analysis 44
8.9 Forecast 44
9 Appendix 46
9.1 Bibliography 46
9.2 Abbreviations 48
9.3 Methodology 52
9.4 Forecasting Methodology 52
9.4.1 Diagnosed UC Patients 52
9.4.2 Percent Drug-Treated Patients 53
9.4.3 General Pricing Assumptions 53
9.4.4 Generic Erosion 54
9.4.5 Pricing of Pipeline Agents 54
9.5 Physicians and Specialists Included in This Study 55
9.6 Primary Research – Prescriber Survey 56
9.7 About the Authors 57
9.7.1 Author 57
9.8 About GlobalData 58
9.9 Disclaimer 58